A negative association between cancer and Alzheimer’s disease (AD) was revealed.
Objective:
We aimed to further explore the dementia risk among cancer survivors and then among cancer survivors who received cancer treatment in subsequent subgroup analyses.
Methods:
Databases of PubMed, Embase, and Cochrane Library were systematically searched from inception to April 1, 2021, following PRISMA and MOOSE guidelines. Relative risks (RR) of dementia were pooled by a random-effects model stratifying the data by potential confounding factors to explore the heterogeneity. This study is registered with PROSPERO, number CRD42021250654.
Results:
A total of 36 studies were included in this meta-analysis, of which 16 studies were about the risk of dementia in cancer survivors, and 20 studies were about the risk of dementia in survivors who accepted cancer treatment. The pooled RR reached 0.89 ([95% CI = 0.82–0.97], I2 = 97.9%) for dementia and 0.89 ([0.83–0.95], I2 = 92.6%) for AD in cancer survivors compared with non-cancer controls. Notably, both dementia risk and AD risk significantly decreased in survivors of colon, leukemia, small intestine, and thyroid cancers (RR ranged from 0.64 to 0.92). Furthermore, prostate cancer patients treated with androgen deprivation therapy exhibited a significantly increased risk of dementia (RR:1.18 [1.09–1.27], I2 = 89.5%) and AD (RR:1.17 [1.08–1.25], I2 = 81.3%), with evidence of between-study heterogeneity.
Conclusion:
Currently, available evidence suggests that the risk of dementia among cancer survivors is decreased. However, large-scale prospective cohort studies are warranted to further prove the association.
van der WillikKD, SchagenSB, IkramMA (2020) Association between the tumor marker carcinoembryonic antigen and the risk of dementia. J Alzheimers Dis76, 845–851.
OssenkoppeleR, JansenWJ, RabinoviciGD, KnolDL, van der FlierWM, van BerckelBN, ScheltensP, VisserPJ, Amyloid PET Study Group, VerfaillieSC, ZwanMD, AdriaanseSM, LammertsmaAA, BarkhofF, JagustWJ, MillerBL, RosenHJ, LandauSM, VillemagneVL, RoweCC, LeeDY, NaDL, SeoSW, SarazinM, RoeCM, SabriO, BarthelH, KoglinN, HodgesJ, LeytonCE, VandenbergheR, van LaereK, DrzezgaA, ForsterS, GrimmerT, Sanchez-JuanP, CarrilJM, MokV, CamusV, KlunkWE, CohenAD, MeyerPT, HellwigS, NewbergA, FrederiksenKS, FleisherAS, MintunMA, WolkDA, NordbergA, RinneJO, ChetelatG, LleoA, BlesaR, ForteaJ, MadsenK, RodrigueKM, BrooksDJ (2015) Prevalence of amyloid PET positivity in dementia syndromes: A meta-analysis. JAMA313, 1939–1949.
4.
CipolliniV, TroiliF, GiubileiF (2019) Emerging biomarkers in vascular cognitive impairment and dementia: From pathophysiological pathways to clinical application. Int J Mol Sci20, 2812.
5.
SiegelRL, MillerKD, JemalA (2020) Cancer statistics, 2020. CA Cancer J Clin70, 7–30.
6.
di PietroM, CantoMI, FitzgeraldRC (2018) Endoscopic management of early adenocarcinoma and squamous cell carcinoma of the esophagus: Screening, diagnosis, and therapy. Gastroenterology154, 421–436.
7.
MottetN, BellmuntJ, BollaM, BriersE, CumberbatchMG, De SantisM, FossatiN, GrossT, HenryAM, JoniauS, LamTB, MasonMD, MatveevVB, MoldovanPC, van den BerghRCN, Van den BroeckT, van der PoelHG, van der KwastTH, RouvièreO, SchootsIG, WiegelT, CornfordP (2017) EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol71, 618–629.
8.
SiegelRL, MillerKD, JemalA (2019) Cancer statistics, 2019. CA Cancer J Clin69, 7–34.
9.
ZhangQ, GuoS, ZhangX, TangS, ShaoW, HanX, WangL, DuY (2015) Inverse relationship between cancer and Alzheimer’s disease: A systemic review meta-analysis. Neurol Sci36, 1987–1994.
10.
MaLL, YuJT, WangHF, MengXF, TanCC, WangC, TanL (2014) Association between cancer and Alzheimer’s disease: Systematic review and meta-analysis. J Alzheimers Dis42, 565–573.
11.
Ospina-RomeroM, GlymourMM, Hayes-LarsonE, MayedaER, GraffRE, BrenowitzWD, AckleySF, WitteJS, KobayashiLC (2020) Association between Alzheimer disease and cancer with evaluation of study biases: A systematic review and meta-analysis. JAMA Netw Open3, e2025515.
12.
WhiteRS, LiptonRB, HallCB, SteinermanJR (2013) Nonmelanoma skin cancer is associated with reduced Alzheimer disease risk. Neurology80, 1966–1972.
13.
IbáñezK, BoullosaC, Tabarés-SeisdedosR, BaudotA, ValenciaA (2014) Molecular evidence for the inverse comorbidity between central nervous system disorders and cancers detected by transcriptomic meta-analyses. PLoS Genet10, e1004173.
14.
Sari MotlaghR, QuhalF, MoriK, MiuraN, AydhA, LaukhtinaE, PradereB, KarakiewiczPI, EnikeevDV, DeukerM, ShariatSF (2021) The risk of new onset dementia and/or Alzheimer disease among patients with prostate cancer treated with androgen deprivation therapy: A systematic review and meta-analysis. J Urol205, 60–67.
15.
NeadKT, SinhaS, NguyenPL (2017) Androgen deprivation therapy for prostate cancer and dementia risk: A systematic review and meta-analysis. Prostate Cancer Prostatic Dis20, 259–264.
16.
PapageorgakopoulosTN, MoraitouD, PapanikolaouM, TsolakiM (2017) The association between Alzheimer’s disease and cancer: Systematic review - Meta-analysis. Hell J Nucl Med20(Suppl), 45–57.
17.
BernsteinLJ, McCreathGA, RichJB (2017) A meta-analysis of cognitive impairment in breast cancer survivors treated with chemotherapy.P4-. Cancer Res77(4 Suppl), 19–03.
18.
MoherD, LiberatiA, TetzlaffJ, AltmanDG (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ339, b2535.
19.
WellsG (2014) The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in metaanalyses. In Symposium on Systematic Reviews: Beyond the Basics.
20.
ChaturvediAK, MbulaiteyeSM, EngelsEA (2008) Underestimation of relative risks by standardized incidence ratios for AIDS-related cancers. Ann Epidemiol18, 230–234.
21.
HigginsJ, GreenSR (2011) Cochrane Handbook for Systematic Review of Interventions, Version 5.1.0.
22.
RileyRD, HigginsJP, DeeksJJ (2011) Interpretation of random effects meta-analyses. BMJ342, d549.
23.
SterneJA, EggerM (2001) Funnel plots for detecting bias in meta-analysis: Guidelines on choice of axis. J Clin Epidemiol54, 1046–1055.
24.
SolomonsL, SolomonsJ, GosneyM (2013) Dementia and cancer: A review of the literature and current practice. Aging Health9, 307–319.
25.
ShiHB, TangB, LiuYW, WangXF, ChenGJ (2015) Alzheimer disease and cancer risk: A meta-analysis. J Cancer Res Clin Oncol141, 485–494.
26.
CuiH, WangY, LiF, HeG, JiangZ, GangX, WangG (2021) Quantifying observational evidence for risk of dementia following androgen deprivation therapy for prostate cancer: An updated systematic review and meta-analysis. Prostate Cancer Prostatic Dis24, 15–23.
27.
HernánMA, AlonsoA, LogroscinoG (2008) Cigarette smoking and dementia: Potential selection bias in the elderly. Epidemiology19, 448–450.
28.
FedericoA, MorgilloF, TuccilloC, CiardielloF, LoguercioC (2007) Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer121, 2381–2386.
29.
MuleroJ, ZafrillaP, Martinez-CachaA (2011) Oxidative stress, frailty and cognitive decline. J Nutr Health Aging15, 756–760.
30.
DriverJA, LuKP (2010) Pin1: A new genetic link between Alzheimer’s disease, cancer and aging. Curr Aging Sci3, 158–165.
31.
DriverJA (2014) Inverse association between cancer and neurodegenerative disease: Review of the epidemiologic and biological evidence. Biogerontology15, 547–557.
32.
LiuS, HuangZ, ZhangL, PanJ, LeiQ, MengY, LiZ (2020) Plasma neurofilament light chain may be a biomarker for the inverse association between cancers and neurodegenerative diseases. Front Aging Neurosci12, 10.
33.
KyzasPA, Denaxa-KyzaD, IoannidisJP (2007) Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer43, 2559–2579.
34.
BoffettaP, McLaughlinJK, La VecchiaC, TaroneRE, LipworthL, BlotWJ (2008) False-positive results in cancer epidemiology: A plea for epistemological modesty. J Natl Cancer Inst100, 988–995.
35.
TsilidisKK, PapatheodorouSI, EvangelouE, IoannidisJP (2012) Evaluation of excess statistical significance in meta-analyses of 98 biomarker associations with cancer risk. J Natl Cancer Inst104, 1867–1878.
36.
IoannidisJP, ZhouY, ChangCQ, SchullySD, KhouryMJ, FreedmanAN (2014) Potential increased risk of cancer from commonly used medications: An umbrella review of meta-analyses. Ann Oncol25, 16–23.
37.
KyzasPA, LoizouKT, IoannidisJP (2005) Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst97, 1043–1055.
38.
KavvouraFK, LiberopoulosG, IoannidisJP (2007) Selection in reported epidemiological risks: An empirical assessment. PLoS Med4, e79.
39.
IoannidisJP (2012) The importance of potential studies that have not existed and registration of observational data sets. JAMA308, 575–576.
40.
CarcaillonL, Brailly-TabardS, AncelinML, TzourioC, Foubert-SamierA, DartiguesJF, Guiochon-MantelA, ScarabinPY (2014) Low testosterone and the risk of dementia in elderly men: Impact of age and education. Alzheimers Dement10, S306–314.
41.
RosarioER, ChangL, StanczykFZ, PikeCJ (2004) Age-related testosterone depletion and the development of Alzheimer disease. JAMA292, 1431–1432.
42.
VestRS, PikeCJ (2013) Gender, sex steroid hormones, and Alzheimer’s disease. Horm Behav63, 301–307.
43.
ShafferVA, MerkleEC, FagerlinA, GriggsJJ, LangaKM, IwashynaTJ (2012) Chemotherapy was not associated with cognitive decline in older adults with breast and colorectal cancer: Findings from a prospective cohort study. Med Care50, 849–855.
44.
XuZ, LuoF, WangY, ZouBS, ManY, LiuJS, LiH, ArshadB, LiH, LiS, WeiYX, LiHY, WuKN, KongLQ (2020) Cognitive impairments in breast cancer survivors treated with chemotherapy: A study based on event-related potentials. Cancer Chemother Pharmacol85, 61–67.
45.
JungMS, CimprichB (2014) Cognitive deficits in Korean women treated with chemotherapy for breast cancer. Cancer Nurs37, E31–42.
46.
CorreaDD, AhlesTA (2007) Cognitive adverse effects of chemotherapy in breast cancer patients. Curr Opin Support Palliat Care1, 57–62.
47.
WulfGM, RyoA, WulfGG, LeeSW, NiuT, PetkovaV, LuKP (2001) Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J20, 3459–3472.
48.
BaoL, KimzeyA, SauterG, SowadskiJM, LuKP, WangDG (2004) Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am J Pathol164, 1727–1737.
49.
IoannidisJP (2008) Why most discovered true associations are inflated. Epidemiology19, 640–648.
RoeCM, FitzpatrickAL, XiongC, SiehW, KullerL, MillerJP, WilliamsMM, KopanR, BehrensMI, MorrisJC (2010) Cancer linked to Alzheimer disease but not vascular dementia. Neurology74, 106–112.
52.
DriverJA, BeiserA, AuR, KregerBE, SplanskyGL, KurthT, KielDP, LuKP, SeshadriS, WolfPA (2012) Inverse association between cancer and Alzheimer’s disease: Results from the Framingham Heart Study. BMJ344, e1442.
53.
MusiccoM, AdorniF, DiSanto S, PrinelliF, PettenatiC, CaltagironeC, PalmerK, RussoA (2013) Inverse occurrence of cancer and Alzheimer disease: A population-based incidence study. Neurology81, 322–328.
54.
FreedmanDM, WuJ, ChenH, KunclRW, EnewoldLR, EngelsEA, FreedmanND, PfeifferRM (2016) Associations between cancer and Alzheimer’s disease in a U.S. Medicare population. Cancer Med5, 2965–2976.
55.
SunLM, ChenHJ, LiangJA, KaoCH (2016) Long-term use of tamoxifen reduces the risk of dementia: A nationwide population-based cohort study. QJM109, 103–109.
56.
ChungSD, LinHC, TsaiMC, KaoLT, HuangCY, ChenKC (2016) Androgen deprivation therapy did not increase the risk of Alzheimer’s and Parkinson’s disease in patients with prostate cancer. Andrology4, 481–485.
57.
FrainL, SwansonD, ChoK, GagnonD, LuKP, BetenskyRA, DriverJ (2017) Association of cancer and Alzheimer’s disease risk in a national cohort of veterans. Alzheimers Dement13, 1364–1370.
58.
BowlesEJA, WalkerRL, AndersonML, DublinS, CranePK, LarsonEB (2017) Risk of Alzheimer’s disease following a cancer diagnosis. Alzheimers Dement13, P516.
59.
HansonHA, HornKP, RasmussenKM, HoffmanJM, SmithKR (2017) Is cancer protective for subsequent Alzheimer’s disease risk? Evidence from the Utah Population Database. J Gerontol B Psychol Sci Soc Sci72, 1032–1043.
60.
IblerE, TranG, OrrellKA, SerranoL, MajewskiS, SableKA, ThiedeR, LaumannAE, WestDP, NardoneB (2018) Inverse association for diagnosis of Alzheimer’s disease subsequent to both melanoma and non-melanoma skin cancers in a large, urban, single-centre, Midwestern US patient population. J Eur Acad Dermatol Venereol32, 1893–1896.
61.
OrdingAG, Horváth-PuhóE, VeresK, GlymourMM, RørthM, SørensenHT, HendersonVW (2020) Cancer and risk of Alzheimer’s disease: Small association in a nationwide cohort study. Alzheimers Dement16, 953–964.
62.
SunM, WangY, SundquistJ, SundquistK, JiJ (2020) The association between cancer and dementia: A national cohort study in Sweden. Front Oncol10, 73.
63.
KangJ, ShinDW, HanK, ParkSH, LeeWG, YooJE, WooSH, ParkJ (2020) Risk of dementia in prostate cancer survivors: A nationwide cohort study in Korea. Curr Probl Cancer44, 100578.
64.
ChamberlainJD, RouanetA, DuboisB, PasquierF, HanonO, GabelleA, CeccaldiM, Krolak-SalmonP, BéjotY, GodefroyO, WallonD, GentricA, ChêneG, DufouilC (2021) Investigating the association between cancer and the risk of dementia: Results from the Memento cohort. Alzheimers Dement17, 1415–1421.
